Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.

Toshiyuki SumiMotoki SekikawaYuta KoshinoDaiki NagayamaYuta NagahisaKeigo MatsuuraNaoki ShijubouKoki KamadaKeito SuzukiTakumi IkedaHaruhiko MichimataHiroki WatanabeYuichi YamadaKoichi OsudaYusuke TanakaHirofumi Chiba

Published in: Thoracic cancer (2024)

Vigilant monitoring and early intervention are crucial for patients with squamous cell carcinoma, high SP-D level, or low %DLCO undergoing ipilimumab plus nivolumab therapy.

Keyphrases

squamous cell carcinoma
randomized controlled trial
early onset
interstitial lung disease
drug induced
stem cells
systemic sclerosis
bone marrow
idiopathic pulmonary fibrosis
cell therapy